Zydus Cadila gets approval for Hydroxychloroquine Sulfate

Published on Tue, Sep 25, 2007 at 18:04 |  Source : Moneycontrol.com

Updated at Tue, Sep 25, 2007 at 18:30  

Like this story, share it with millions of investors on M3
0
0
Share on Tumblr

RELATED NEWS

Zydus Cadila has received an approval from the USFDA for Hydroxychloroquine Sulfate Tablets in the strength of 200 mg. The drug falls in the DMARD (Disease Modifying Anti-Rheumatic Drug) segment and is used in the management of rheumatoid arthritis. The sales of Hydroxychloroquine Sulfate Tablets in the US market in 2006 as per NDC Health was estimated at USD $ 30 mn.

The company will market the drug through its US subsidiary Zydus Pharmaceuticals (USA) Inc. The group has 27 approvals since the commencement of filing process in  FY 2003-04. So far, the group has filed 65 ANDAs and 55 DMFs.
 

 

Sourced From: Pressman India

  

More on Moneycontrol

Trending News

Business News

No entry fee to migrate to Unified License, proposes TRAI
Rupee rally may stall with fall against US dollar, euro "Rupee rally may stall with fall against US dollar, euro"

Sources Say 'Meet To Decide If Govt Should Move Leave Plea On SC Order'

The latest earning numbers FIRST on CNBC-TV18
Videos

Feb 10 2012, 21:39

Tulsian buys steel stocks; negative on sugar, ADAG

- in MARKET OUTLOOK

Feb 10 2012, 21:39

Truck demand sluggish; margins down 80bps: Shriram Trans

- in Results Boardroom

Interviews

Feb 10 2012, 15:43 | Source: CNBC-TV18

Growth in margins sustainable going forward: Shasun Pharma  

Feb 10 2012, 15:35 | Source: CNBC-TV18

Expect Q4 GRMs to be similar to Q3: BPCL  

Subscribe to

Moneycontrol Newsletters

Moneycontrol.com offers you a choice of various sectoral and other newsletters for FREE!

Follow moneycontrol.com